All relevant data are within the paper and its Supporting Information files.

Introduction {#sec010}
============

Surgical resections remain the mainstay of potentially curative treatment for resectable oesophageal cancer \[[@pone.0132889.ref001]--[@pone.0132889.ref006]\]. However, resections for esophageal cancer are invasive, and various surgical techniques for open oesophagectomy (OE) have been considered to have high mortality and morbidity rates \[[@pone.0132889.ref007]\]. Previous studies found that the occurrence of in-hospital mortality was between 1.2 and 8.8% \[[@pone.0132889.ref007]--[@pone.0132889.ref011]\], even as high as 29% \[[@pone.0132889.ref012]\]. Therefore, in-hospital mortality has often been considered as an outcome indicator for esophageal surgery and used to analyze and compare surgical outcomes among different medical centres \[[@pone.0132889.ref013]\]. Therefore, the exploration for measures to prevent in-hospital death and relevant factor are the hotter and more discussed issues in current studies of esophageal surgery, and any achievement in this aspect may have a deep impact on the clinical treatment of oesophageal cancer.

Minimally invasive oesophagectomy (MIO), first described in 1990s \[[@pone.0132889.ref014]--[@pone.0132889.ref016]\], has superiority in reducing the risk of postoperative morbidity without compromising oncological outcomes through avoiding thoracotomy and laparotomy \[[@pone.0132889.ref004], [@pone.0132889.ref017]--[@pone.0132889.ref020]\]. Theoretically, MIO has an advantage over OE in reduction the risk of IHM to a larger extent. Nevertheless, this theoretical assumption has never been subjected to empirical verification \[[@pone.0132889.ref020]--[@pone.0132889.ref033]\]. Instead, previous meta-analyses \[[@pone.0132889.ref022]--[@pone.0132889.ref033]\], relevant studies \[[@pone.0132889.ref004]--[@pone.0132889.ref006]\] and even randomized controlled trials \[[@pone.0132889.ref003]\] of available evidences have suggested a potential advantage of MIO in reducing the incidence of morbidity, rather than in reducing mortality.

Thus, at least two critical questions concerning esophageal surgery are of considerable interest and remain unanswered: i) does MIO have superiority in reducing the occurrence of IHM?; ii) what are the factors affecting the occurrence of IHM? These questions are important for both future research and current clinical practice. For this reason, we conducted a systematic review and meta-analysis to comprehensively assess the superiority of MIO in reducing the occurrence of IHM, with the aim to provide meaningful clues for esophageal surgery.

Methods {#sec011}
=======

Data sources and searches {#sec012}
-------------------------

Medline (through December 31, 2014), Embase (through December 31, 2014), Wiley Online Library (through December 31, 2014), and the Cochrane Library, (through December 31, 2014) were searched, using the terms "Minimally invasive oesophagectomy, oesophageal cancer, oesophageal carcinoma,open oesophagectomy". This review protocol was registered and published in the International Prospective Register of Systematic Reviews, PROSPERO (Registration No. CRD42014012901), following the prescribed steps \[[@pone.0132889.ref034]\]. This report complies with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) \[[@pone.0132889.ref035]--[@pone.0132889.ref036]\].

Study Selection and Eligibility Criteria {#sec013}
----------------------------------------

Included studies had to meet the following criteria: i) research articles published in English; ii) randomized or non-randomized controlled studies with parallel controls; iii) studies comparing MIO with OE; iv) grey literature such as conference proceedings, reports and other peer-reviewed research.

Publications were excluded: i) if the outcomes of interest was not reported or it was impossible to calculate the outcomes from the published results; ii) if a distinct group of patients was not mentioned or the outcomes of interest were not compared; iii) if publications belong to systematic reviews or meta-analysis.

Data collection and Quality Assessment {#sec014}
--------------------------------------

All eligible studies were retrieved and evaluated by two independent reviewers. Disagreements on inclusion were discussed, if necessary, with the guidance of the corresponding authors of these studies via E-mail. If no response was received, a second E-mail was sent one week later.

To ascertain the validity of eligible studies, study quality was appraised in reference to the 12 items described in methodological index for non-randomized studies (MINORS) \[[@pone.0132889.ref037]\]. The total quality scores ranged from 0 (low quality) to 24 (high quality). Disagreement on study quality was resolved by discussion with corresponding authors of these studies via E-mail or personal interview.

Outcomes Definition {#sec015}
-------------------

IHM was defined as hospital mortality, inpatient mortality, mortality within 30 days of hospitalization, in-patient death, death in hospital, or mortality. The broad definition of MIO was thoracoscopic/laparotomy assisted oesophagectomy, hybrid minimally invasive oesophagectomy and total thoracoscopic/ laparoscopic oesophagectomy, or minimally invasive oesophagectomy (MIE). Pulmonary complications were defined as respiratory complications, pulmonary infection, pneumonia, respiratory failure, adult respiratory distress syndrome, atelectasis, etc., but did not include adult respiratory distress syndrome. Arrhythmia was defined as atrial arrhythmia or atrial fibrillation.

Data synthesis and analysis {#sec016}
---------------------------

In-hospital mortality was the primary outcome measure, as it was considered an outcome indicator for esophageal surgery and has been used to analyze and compare surgical outcomes among different medical centres. Secondary outcome measures included pulmonary complications, pulmonary embolism, anastomotic leak, gastric tip necrosis, and arrhythmia, for the reason that they are underlying causes of in-hospital mortality. Fixed or random-effects models \[[@pone.0132889.ref038]\] were used in this meta-analysis. Forest plots were provided to illustrate pooled relative risks (RRs) or odds ratios (ORs), and corresponding 95% confidence intervals (CIs). The consistency of results (effect sizes) among studies was investigated by means of I^2^ statistics \[[@pone.0132889.ref039]\]. When the heterogeneity test was statistically significant, a random effects model was used, otherwise, a fixed effects model was used. Heterogeneity was interpreted according to the thresholds outlined in the Cochrane Handbook: 0% to 40%- low heterogeneity, 30% to 60%- moderate heterogeneity, 50% to 90%-possible substantial heterogeneity, 75% to 100%- considerable heterogeneity. If the heterogeneity was high \[[@pone.0132889.ref040]\] (I^2^\>50% or P\<0.10), sensitivity analysis and subgroup analysis were performed to find out potential origin of heterogeneity.

Egger\'s test and Begg's funnel plot were used for diagnosis of potential publication bias \[[@pone.0132889.ref041]\]. In addition, the possible effect of publication bias in our meta-analysis was further assessed using Duval and Tweedie nonparametric "trim and fill" procedure \[[@pone.0132889.ref042]\]. This method considers the possibility of hypothetical "missing" studies that might exist, imputes their RRs, and recalculates a pooled RR that incorporates the hypothetical "missing" studies as though they actually existed.

All statistical processes were performed with Stata version 12.0 software (Stata Corp LP, College Station, TX, USA).

Results {#sec017}
=======

Selected studies and methodological quality {#sec018}
-------------------------------------------

The steps of our literature search are shown in [Fig 1](#pone.0132889.g001){ref-type="fig"}. A total 3,326 unique records were identified from the electronic databases. Of these, 1,075 records were excluded for duplicated ones, 2,175 records were excluded for meeting the exclusion criteria. After an initial screening of titles and abstracts, 76 potential articles were included for full-text view \[[@pone.0132889.ref003], [@pone.0132889.ref004], [@pone.0132889.ref006], [@pone.0132889.ref021]--[@pone.0132889.ref033], [@pone.0132889.ref043]--[@pone.0132889.ref102]\]. Twenty-eight articles were excluded after additional screening, with the reasons that: i) 12 studies were meta-analyses or systematic overviews \[[@pone.0132889.ref022]--[@pone.0132889.ref033]\]; ii) 14 studies did not compare the outcomes of interest \[[@pone.0132889.ref089]--[@pone.0132889.ref102]\]; iii) 2 studies were retrieved from the same registry \[[@pone.0132889.ref053],[@pone.0132889.ref062]\] and contained an overlapping group of patients with the recent publications \[[@pone.0132889.ref075],[@pone.0132889.ref078]\]. Thus, in total, 48 articles with 14,311 patients undergoing MIO versus OE were included in this systematic review and meta-analysis.

![Flow Diagram of the search and selection method.](pone.0132889.g001){#pone.0132889.g001}

The evaluation results of the methodological quality of the studies are shown in [Table 1](#pone.0132889.t001){ref-type="table"}. The quality scores of the included studies ranged from 16 to 20 ([Table 1](#pone.0132889.t001){ref-type="table"}). None of the included studies performed a prospective calculation of the study size or an unbiased assessment of study outcomes. A randomized controlled design was done in only one study \[[@pone.0132889.ref004]\].

10.1371/journal.pone.0132889.t001

###### Characteristics and Demographics of Included Studies.

![](pone.0132889.t001){#pone.0132889.t001g}

  Study                                          Year   Country       Design   Cases   MINORS   Adeno.%   Hybrid   TNM stage                     
  ---------------------------------------------- ------ ------------- -------- ------- -------- --------- -------- ----------- ----- ----- ----- -----
  Law S^\[[@pone.0132889.ref043]\]^              1997   China         NA       18      63       16        NA       MIE         5     13    15    48
  Nguyen NT^\[[@pone.0132889.ref044]\]^          2000   USA           R        18      36       16        NA       MIE         NA    NA    NA    NA
  Osugi H^\[[@pone.0132889.ref045]\]^            2003   Japan         P        77      72       20        0        TA          NA    NA    NA    NA
  Kunisaki C^\[[@pone.0132889.ref046]\]^         2004   Japan         P        15      30       16        NA       MIE         NA    NA    NA    NA
  Van den Broek WT^\[[@pone.0132889.ref047]\]^   2004   Netherlands   NA       25      20       19        71.1     TA          8     17    10    10
  Braghetto I^\[[@pone.0132889.ref048]\]^        2006   Chile         R        47      119      20        NA       MIE         41    6     29    90
  Bresadola V^\[[@pone.0132889.ref049]\]^        2006   Italy         NA       14      14       16        NA       MIE         11    3     6     8
  Shiraishi T^\[[@pone.0132889.ref050]\]^        2006   Japan         R        116     37       16        NA       Hybrid      NA    NA    NA    NA
  Benzoni E^\[[@pone.0132889.ref051]\]^          2007   Italy         P        9       13       20        23.8     TA          9     0     7     6
  Smithers BM^\[[@pone.0132889.ref003]\]^        2007   Australia     P        332     114      20        70.6     Hybrid      192   118   36    75
  Fabian T^\[[@pone.0132889.ref052]\]^           2008   USA           R        22      43       20        69.2     MIE         14    7     25    19
  Parameswaran R^\[[@pone.0132889.ref054]\]^     2009   UK            NA       50      30       19        82.5     MIE         27    23    17    15
  Perry KA^\[[@pone.0132889.ref055]\]^           2009   USA           P        21      21       16        45.2     MIE         NA    NA    NA    NA
  Saha AK^\[[@pone.0132889.ref056]\]^            2009   UK            NA       16      28       19        16+      MIE         NA    NA    NA    NA
  Zingg U^\[[@pone.0132889.ref057]\]^            2009   Australia     NA       56      98       20        72.1     MIE         35    21    47    42
  Hamouda AH^\[[@pone.0132889.ref058]\]^         2010   UK            P        51      24       16        80       MIE         NA    NA    NA    NA
  Pham TH^\[[@pone.0132889.ref021]\]^            2010   USA           P        44      46       16        74.4     MIE         20    20    20    19
  Safranek PM^\[[@pone.0132889.ref059]\]^        2010   UK            P        75      46       16        NA       Hybrid      31    44    29    17
  Schoppmann SF^\[[@pone.0132889.ref060]\]^      2010   Australia     P        31      31       20        46.8     MIE         14    15    13    17
  Schröder W^\[[@pone.0132889.ref061]\]^         2010   Germany       R        238     181      16        60.1     TA          NA    NA    NA    NA
  Wang H^\[[@pone.0132889.ref063]\]^             2010   China         NA       27      29       16        5.3      TA          24    3     24    5
  Berger AC^\[[@pone.0132889.ref064]\]^          2011   USA           NA       65      53       16        79.7     MIE         52    13    41    12
  Gao Y^\[[@pone.0132889.ref065]\]^              2011   China         R        96      78       16        5.2      MIE         54    42    40    38
  Lee JM^\[[@pone.0132889.ref066]\]^             2011   Japan         P        74      64       20        5.1      Hybrid      45    20    49    15
  Nafteux P^\[[@pone.0132889.ref067]\]^          2011   Belgium       R        65      101      16        75.3     MIE         NA    NA    NA    NA
  Yamasaki M^\[[@pone.0132889.ref068]\]^         2011   Japan         R        109     107      20        NA       TA          NA    NA    NA    NA
  Briez N^\[[@pone.0132889.ref069]\]^            2012   France        P        140     140      20        40.7     TA          92    48    89    51
  Kinjo Y^\[[@pone.0132889.ref070]\]^            2012   Japan         P        106     79       19        3.2      MIE         65    41    45    34
  Maas KW^\[[@pone.0132889.ref071]\]^            2012   Netherlands   R        50      50       20        69       MIE         19    31    19    31
  Mamidanna R^\[[@pone.0132889.ref072]\]^        2012   UK            P        1155    6347     16        NA       MIE         NA    NA    NA    NA
  Sihag S^\[[@pone.0132889.ref073]\]^            2012   USA           P        38      76       16        85.1     MIE         29    9     53    23
  Sundaram A^\[[@pone.0132889.ref074]\]^         2012   USA           R        47      57       20        78.8     MIE         NA    NA    NA    NA
  Tsujimoto H^\[[@pone.0132889.ref075]\]^        2012   Japan         NA       22      27       16        NA       TA          9     11    19    18
  Bailey L^\[[@pone.0132889.ref076]\]^           2013   UK            P        39      31       20        82.9     TA          NA    NA    NA    NA
  Biere SS^\[[@pone.0132889.ref004]\]^           2013   Netherlands   RCT      59      56       18        61.7     MIE         31    15    26    19
  Ichikawa H^\[[@pone.0132889.ref077]\]^         2013   Japan         NA       153     162      20        66.7     TA          101   51    81    79
  Kitagawa H^\[[@pone.0132889.ref078]\]^         2013   Japan         R        45      47       16        4.3      MIE         NA    NA    NA    NA
  Noble F^\[[@pone.0132889.ref079]\]^            2013   UK            P        53      53       19        NA       MIE         NA    NA    NA    NA
  Parameswaran R^\[[@pone.0132889.ref080]\]^     2013   UK            P        67      19       16        75.6     Hybrid      43    23    8     11
  Takeno S^\[[@pone.0132889.ref081]\]^           2013   Japan         R        91      166      20        3.5      TA          NA    NA    NA    NA
  Kubo N^\[[@pone.0132889.ref006]\]^             2014   Japan         R        135     74       16        NA       Hybrid      112   23    41    33
  Mu J^\[[@pone.0132889.ref082]\]^               2014   China         R        176     142      16        NA       MIE         34    18    73    17
  Kauppi J^\[[@pone.0132889.ref083]\]^           2014   Finland       R        74      79       20        NA       MIE         28    46    25    54
  Meng F^\[[@pone.0132889.ref084]\]^             2014   China         R        94      89       20        4.4      MIE         56    38    50    39
  Schneider C^\[[@pone.0132889.ref085]\]^        2014   UK            R        19      61       16        78.8     MIE         16    2     36    24
  Zhang J^\[[@pone.0132889.ref086]\]^            2014   China         R        60      61       16        NA       MIE         NA    NA    NA    NA
  Li J^\[[@pone.0132889.ref087]\]^               2014   China         R        89      318      20        NA       MIE         64    25    188   126
  Javidfar J^\[[@pone.0132889.ref088]\]^         2012   USA           R        92      165      20        86.8     MIE         65    27    96    69

Note: Adeno.: adenocarcinoma; NA: not applicable; MIO: minimally invasive oesophagectomy, including MIE,TA and Hybrid MIE; OE: open esophagectomy; MIE: total minimally invasive esophagectomy; TA: thoracoscopic-assisted MIE; Hybrid: Hybrid minimally invasive oesophagectomy.

Characteristics of studies and patients {#sec019}
---------------------------------------

The 48 studies totaling in 14,311 patients included in this meta-analysis contained 4,509 (30.5%) cases undergoing MIO and 9,793 (69.5%) undergoing OE ([Table 1](#pone.0132889.t001){ref-type="table"}). Of the 48 studies, only 1 was a randomized controlled trial (RCT) \[[@pone.0132889.ref004]\]. Eight studies \[[@pone.0132889.ref054],[@pone.0132889.ref056],[@pone.0132889.ref058],[@pone.0132889.ref059],[@pone.0132889.ref072],[@pone.0132889.ref076],[@pone.0132889.ref079],[@pone.0132889.ref080],[@pone.0132889.ref085]\] were done in the United Kingdom (UN), 8 in the USA \[[@pone.0132889.ref021],[@pone.0132889.ref044],[@pone.0132889.ref052],[@pone.0132889.ref055],[@pone.0132889.ref064],[@pone.0132889.ref073],[@pone.0132889.ref074],[@pone.0132889.ref088]\],11 in Japan \[[@pone.0132889.ref006],[@pone.0132889.ref045],[@pone.0132889.ref046],[@pone.0132889.ref050],[@pone.0132889.ref066],[@pone.0132889.ref068],[@pone.0132889.ref070],[@pone.0132889.ref075],[@pone.0132889.ref077],[@pone.0132889.ref078],[@pone.0132889.ref081]\], 7 in China \[[@pone.0132889.ref043],[@pone.0132889.ref063],[@pone.0132889.ref065],[@pone.0132889.ref082],[@pone.0132889.ref084],[@pone.0132889.ref086], [@pone.0132889.ref087]\], 4 in Australia \[[@pone.0132889.ref003],[@pone.0132889.ref057],[@pone.0132889.ref060],[@pone.0132889.ref067]\],3 in Netherlands \[[@pone.0132889.ref004],[@pone.0132889.ref047],[@pone.0132889.ref071]\], and 2 in Italy \[[@pone.0132889.ref049],[@pone.0132889.ref051]\], and the remaining studies were conducted in Germany \[[@pone.0132889.ref061]\], France \[[@pone.0132889.ref069]\], Chile \[[@pone.0132889.ref048]\], and Finland \[[@pone.0132889.ref083]\]. Key methodological characteristics are shown in [Table 1](#pone.0132889.t001){ref-type="table"}. Thirty-one studies investigated in-hospital mortality (IHM) as an outcome measure, 42 studies for pulmonary complications (PCs), 17 studies for pulmonary embolism (PE), 25 studies for Arrhythmia, 41 studies for Anastomotic Leak (AL) and 17 studies for Gastric Tip Necrosis (GTN) ([Table 2](#pone.0132889.t002){ref-type="table"}).

10.1371/journal.pone.0132889.t002

###### Outcomes of interest in Included Studies.

![](pone.0132889.t002){#pone.0132889.t002g}

  Study                                          Endpoints                                                                                                         
  ---------------------------------------------- ----------- ---------- ---------- ----------- --------- --------- ---------- ---------- -------- -------- ------- -------
  Law S^\[[@pone.0132889.ref043]\]^              NA          NA         3/18       11/63       NA        NA        NA         NA         NA       NA       NA      NA
  Nguyen NT^\[[@pone.0132889.ref044]\]^          NA          NA         2/18       6/36        1/18      1/36      NA         NA         2/18     4/40     0/18    1/36
  Osugi H^\[[@pone.0132889.ref045]\]^            NA          NA         NA         NA          12/149    3/72      2/77       2/77       1/149    2/53     NA      NA
  Kunisaki C^\[[@pone.0132889.ref046]\]^         NA          NA         0/15       1/30        NA        NA        NA         NA         2/15     1/30     NA      NA
  Van den Broek WT^\[[@pone.0132889.ref047]\]^   NA          NA         2/25       2/20        NA        NA        NA         NA         2/25     3/20     NA      NA
  Braghetto I^\[[@pone.0132889.ref048]\]^        3/47        13/119     7/47       22/119      0/47      1/119     NA         NA         4/47     26/119   NA      NA
  Bresadola V^\[[@pone.0132889.ref049]\]^        NA          NA         1/14       2/14        1/14      0/14      NA         NA         1/14     2/14     NA      NA
  Shiraishi T^\[[@pone.0132889.ref050]\]^        6/116       5/37       25/116     12/37       NA        NA        3/116      4/37       13/116   9/56     NA      NA
  Benzoni E^\[[@pone.0132889.ref051]\]^          NA          NA         0/8        1/13        NA        NA        NA         NA         1/8      1/13     0/8     1/13
  Smithers BM^\[[@pone.0132889.ref003]\]^        7/332       3/114      87/332     35/114      NA        NA        55/332     21/114     18/332   10/114   5/332   2/114
  Fabian T^\[[@pone.0132889.ref052]\]^           1/22        4/43       3/22       18/43       1/22      0/43      4/22       8/43       3/22     3/43     1/22    0/43
  Parameswaran R^\[[@pone.0132889.ref054]\]^     NA          NA         4/50       2/30        0/50      1/30      0/50       2/30       4/50     1/30     5/50    2/30
  Perry KA^\[[@pone.0132889.ref055]\]^           NA          NA         2/21       3/21        NA        NA        5/21       8/21       4/21     6/21     NA      NA
  Saha AK^\[[@pone.0132889.ref056]\]^            0/16        2/28       NA         NA          NA        NA        NA         NA         2/16     3/28     NA      NA
  Zingg U^\[[@pone.0132889.ref057]\]^            2/56        6/98       17/56      33/98       NA        NA        NA         NA         11/56    11/98    NA      NA
  Hamouda AH^\[[@pone.0132889.ref058]\]^         NA          NA         15/51      5/24        NA        NA        3/51       6/24       4/51     2/24     3/51    1/24
  Pham TH^\[[@pone.0132889.ref021]\]^            3/44        2/46       13/44      9/46        0/44      2/46      18/44      11/46      4/44     5/46     1/44    1/46
  Safranek PM^\[[@pone.0132889.ref059]\]^        3/75        1/46       19/75      13/46       NA        NA        NA         NA         11/75    1/46     2/75    0/46
  Schoppmann SF^\[[@pone.0132889.ref060]\]^      NA          NA         5/31       17/31       NA        NA        NA         NA         1/31     8/31     0/31    1/31
  Schröder W^\[[@pone.0132889.ref061]\]^         7/238       11/181     NA         NA          NA        NA        NA         NA         18/238   17/181   NA      NA
  Wang H^\[[@pone.0132889.ref063]\]^             NA          NA         1/27       5/29        0/27      1/29      2/27       1/29       5/27     4/29     NA      NA
  Berger AC^\[[@pone.0132889.ref064]\]^          5/65        4/53       5/65       12/53       NA        NA        NA         NA         9/65     6/53     NA      NA
  Gao Y^\[[@pone.0132889.ref065]\]^              2/96        3/78       13/96      11/78       NA        NA        NA         NA         7/96     6/47     NA      NA
  Lee JM^\[[@pone.0132889.ref066]\]^             4/74        8/64       11/74      20/64       NA        NA        NA         NA         10/74    18/60    NA      NA
  Nafteux P^\[[@pone.0132889.ref067]\]^          2/65        2/101      47/65      17/101      NA        NA        NA         NA         5/65     10/101   NA      NA
  Yamasaki M^\[[@pone.0132889.ref068]\]^         0/109       2/107      7/109      15/107      NA        NA        3/109      6/107      6/109    4/166    0/109   2/107
  Briez N^\[[@pone.0132889.ref069]\]^            2/140       10/140     22/140     60/140      NA        NA        NA         NA         8/140    6/140    0/140   1/140
  Kinjo Y^\[[@pone.0132889.ref070]\]^            NA          NA         22/106     31/79       NA        NA        10/106     4/79       8/106    10/29    NA      NA
  Maas KW^\[[@pone.0132889.ref071]\]^            0/50        1/50       9/50       13/50       NA        NA        3/50       6/50       4/50     3/50     NA      NA
  Mamidanna R^\[[@pone.0132889.ref072]\]^        46/1155     274/6347   230/1155   1181/6347   19/1155   92/6347   102/1155   611/6347   NA       NA       NA      NA
  Sihag S^\[[@pone.0132889.ref073]\]^            0/38        2/76       1/38       33/76       0/38      2/76      5/38       12/76      0/38     2/76     NA      NA
  Sundaram A^\[[@pone.0132889.ref074]\]^         2/47        1/57       5/47       19/57       5/47      19/57     9/47       19/57      4/47     4/57     NA      NA
  Tsujimoto H^\[[@pone.0132889.ref075]\]^        1/22        5/27       2/22       10/27       NA        NA        3/22       14/27      7/22     3/31     1/22    0/27
  Bailey L^\[[@pone.0132889.ref076]\]^           2/39        2/31       15/39      18/31       NA        NA        3/39       8/31       NA       NA       NA      NA
  Biere SS^\[[@pone.0132889.ref004]\]^           2/59        1/56       7/59       19/56       1/59      9/56      NA         NA         7/59     4/56     NA      NA
  Ichikawa H^\[[@pone.0132889.ref077]\]^         0/153       8/153      20/153     33/153      NA        NA        17/153     38/153     14/153   27/153   4/153   5/153
  Kitagawa H^\[[@pone.0132889.ref078]\]^         1/45        2/47       6/45       14/47       NA        NA        NA         NA         NA       NA       NA      NA
  Noble F^\[[@pone.0132889.ref079]\]^            NA          NA         18/53      14/53       0/53      1/53      6/53       6/53       5/53     2/53     NA      NA
  Parameswaran R^\[[@pone.0132889.ref080]\]^     3/67        1/19       NA         NA          11/67     2/19      1/67       2/19       NA       NA       9/67    2/19
  Takeno S^\[[@pone.0132889.ref081]\]^           4/91        15/166     NA         NA          NA        NA        NA         NA         NA       NA       NA      NA
  Kubo N^\[[@pone.0132889.ref006]\]^             2/135       2/74       13/135     16/74       NA        NA        NA         NA         10/135   7/74     0/135   2/74
  Mu J^\[[@pone.0132889.ref082]\]^               1/176       1/142      6/176      4/142       NA        NA        NA         NA         12/176   4/142    NA      NA
  Kauppi J^\[[@pone.0132889.ref083]\]^           NA          NA         13/74      15/79       5/74      5/79      14/74      20/79      5/74     5/79     0/74    2/79
  Meng F^\[[@pone.0132889.ref084]\]^             1/94        4/89       9/49       24/89       NA        NA        4/94       11/89      6/94     7/89     NA      NA
  Schneider C^\[[@pone.0132889.ref085]\]^        0/19        2/61       NA         NA          NA        NA        NA         NA         NA       NA       NA      NA
  Zhang J^\[[@pone.0132889.ref086]\]^            NA          NA         4/60       7/61        NA        NA        3/60       5/61       3/60     2/61     NA      NA
  Li J^\[[@pone.0132889.ref087]\]^               3/89        16/318     15/89      76/318      1/89      3/318     7/89       29/318     19/89    45/318   NA      NA
  Javidfar J^\[[@pone.0132889.ref088]\]^         NA          NA         9/92       29/165      3/92      4/165     22/92      46/165     5/92     7/165    2/92    2/165

Note: NA: not applicable; MIO: minimally invasive oesophagectomy, including MIE, thoracoscopic-assisted MIE and Hybrid MIE; OE: open esophagectomy.

Large variations existed in the pathological types of the tumors: 32 studies reported the cases of adenocarcinoma, with the proportions ranging from 0% to 86.8%, whereas 16 studies failed to mention the pathological types. In addition, 31studies involved total MIE, 11 studies thoracoscopic- assisted MIE (TA), and 6 studies Hybrid (some cases underwent TA while some underwent MIE). In addition, TNM stage were reported in 31 studies totaling in 4440 cases, of whom 63.5% (1,346/2,119) were early stage (stage I and II) of esophageal cancer in the MIO group, and only 54.2% (1,257/2,321) were early stage in the OE group.

Results {#sec020}
=======

MIO and Risk of In-hospital Mortality (IHM) {#sec021}
-------------------------------------------

Thirty-one trials including a total of 13,117 patients were included, with an overall in-hospital mortality (IHM) rate of 4.0% (528/13,117). Of the 13,267 patients, 4.6% (413/8,968) were allocated to OE group and 3.0% (115/3,774) were allocated to MIO group, As shown in [Fig 2](#pone.0132889.g002){ref-type="fig"}, the pooled OR of 0.69 (95%CI = 0.55--0.86) indicated a significant reduction in the risk of IHM after treated with MIO, with no heterogeneity among the included studies (I^2^ = 0%, p = 0.953).

![MIO and Risk of In-Hospital Mortality (IHM).](pone.0132889.g002){#pone.0132889.g002}

MIO and Risk of Pulmonary complications (PCs) {#sec022}
---------------------------------------------

Data for pulmonary complications (PCs) was available for 42 studies or 13,267 cases. Of the 13,267 patients included in these studies, 17.8% (715/4,006) of the patients were allocated to MIO group and 20.4% (1,888/9,261) of the patients allocated to OE group developed PCs, with an overall morbidity of 19.6% (2,603/13,267).

As shown in [Fig 3](#pone.0132889.g003){ref-type="fig"}, due to a statistically significant heterogeneity (I^2^ = 52.0%, p\<0.001), random-effects model as well as subgroup analysis was performed. The pooled RR of 0.73 (95%CI = 0.62--0.86) revealed a significant effect of MIO in reducing the risk of PCs. A consistent result from the subgroup analysis (RR = 0.69, 95% CI: 0.61--0.77) after removing two studies \[[@pone.0132889.ref067], [@pone.0132889.ref072]\], which might be the source of heterogeneity, demonstrated that MIO intervention was associated with a difference in the occurrence of PCs ([Fig 3](#pone.0132889.g003){ref-type="fig"}), with no significant heterogeneity (I^2^ = 0%, p = 0.501).

![MIO and Risk of Pulmonary Complications (PCs).](pone.0132889.g003){#pone.0132889.g003}

MIO and Risk of Pulmonary Embolism (PE) {#sec023}
---------------------------------------

Seventeen studies, including a total of 9,585 patients, evaluated the efficacy of MIO in reducing the risk of pulmonary embolism (PE). Of the 9,585 patients, 2,045 underwent OE and 7,540 underwent MIO, with an overall PE morbidity of 2.3% (217/9,585). As shown in [Fig 4](#pone.0132889.g004){ref-type="fig"}, the pooled OR of 0.71 (95% CI = 0.51--0.99) showed an obvious downward trend of the PE morbidity, with no heterogeneity (I^2^ = 18.1%, p = 0.242).

![MIO and Risk of Pulmonary Embolism (PE).](pone.0132889.g004){#pone.0132889.g004}

MIO and Risk of Arrhythmia {#sec024}
--------------------------

Twenty five trials, including a total of 11,115 participants, of whom 2,983 underwent OE and 8,132 underwent MIO, evaluated the efficacy of MIO in reducing the risk of arrhythmia. Of these participants, 10.2% (305/2,983) of the patients in MIO group and 11.0% (900/8,132) in OE group developed arrhythmia, with an overall morbidity of 10.8% (1,205/11,115). It can be seen that the MIO group, as shown in [Fig 5](#pone.0132889.g005){ref-type="fig"}, showed a significant decrease in the morbidity of arrhythmia (OR = 0.79, 95%CI = 0.68--0.92), with no heterogeneity among different studies (I^2^ = 14.5%, P = 0.257).

![MIO and Risk of Arrhythmia.](pone.0132889.g005){#pone.0132889.g005}

MIO and Risk of Anastomotic Leak (AL) {#sec025}
-------------------------------------

Forty-one studies carried out on 6,188 patients assessed the effect of MIO on anastomotic leak (AL). Of these patients, 3,152 patients underwent MIO and 3,036 patients underwent OE, with an overall AL morbidity of 9.1% (566/6,188). [Fig 6](#pone.0132889.g006){ref-type="fig"} showed that there was no difference in the occurrence of AL between the MIO and OE groups (OR = 0.93, 95%CI = 0.78--1.11). No heterogeneity was detected among the different studies (I^2^ = 14.9%, P = 0.208).

![MIO and Risk of Anastomotic Leak (AL).](pone.0132889.g006){#pone.0132889.g006}

MIO and Risk of Gastric Tip Necrosis (GTN) {#sec026}
------------------------------------------

Seventeen studies, including a total of 2,570 participants, investigated gastric tip necrosis (GTN) as an outcome measure. Of the included patients, 2.3% (33/1,423) of the patients in MIO group and 2.0% (23/1,147) in OE group developed GTN, with an overall morbidity of 2.2% (56/2,570). The pooled OR 0.89 (95%CI = 0.54--1.49) in [Fig 7](#pone.0132889.g007){ref-type="fig"} showed that no significant difference was found between the two groups, with no heterogeneity (I^2^ = 0.0%, p = 0.939).

![MIO and Risk of Gastric Tip Necrosis (GTN).](pone.0132889.g007){#pone.0132889.g007}

Publication Bias Analysis {#sec027}
-------------------------

Egger\'s test and Begg's funnel plots ([S1 Fig](#pone.0132889.s002){ref-type="supplementary-material"}) were used to assess the publication bias among the included studies. An asymmetric funnel plots figure was shown in [S1 Fig](#pone.0132889.s002){ref-type="supplementary-material"}, with significantly statistical differences (P\<0.05) through Egger\'s test ([S1 Table](#pone.0132889.s001){ref-type="supplementary-material"}). This raises the possibility of publication bias. Because of this, we undertook a sensitivity analysis using the trim and fill method, with the aim to impute hypothetically negative unpublished studies to mirror the positive studies that cause funnel plot asymmetry \[[@pone.0132889.ref042]\]. The pooled analyses after incorporating the hypothetical studies showed consistent results which revealed a statistically significant association between MIO and the risk of IHM.

Sensitivity Analysis {#sec028}
--------------------

In the analysis of MIO and risk PCs, sensitivity analyses using the "metaninf" Stata command ([S2 Fig](#pone.0132889.s003){ref-type="supplementary-material"}) indicated that two independent studies \[[@pone.0132889.ref067], [@pone.0132889.ref072]\], were the main origin of heterogeneity. The heterogeneity was vanished after deletion of the two studies above-mentioned, while the association still kept significant ([Fig 3](#pone.0132889.g003){ref-type="fig"}). In addition, no other single study influenced the pooled ORs or RRs qualitatively, as indicated by sensitivity analyses, suggesting that the results of this meta-analysis are stable.

Discussion {#sec029}
==========

As previously described, minimally invasive oesophagectomy (MIO) has been in existence for almost 20 years and has been used as an option for the curative treatment of esophageal cancer in some centres around the world \[[@pone.0132889.ref028]\]. Our systematic review and meta-analysis assessed the superiority of MIO in reducing IHM in 14,302 patients from 48 published studies. The major findings of the current meta-analysis provide proof that administration of MIO can significantly decrease the IHM rate in patients with resectable esophageal cancer.

As we have mentioned before, in-hospital mortality (IHM) is an objective, reliable, precise, and bias-free measurement for patients with surgery in hospital databases. The overall IHM rate of 4.0% we found in our meta-analysis was slightly lower than 5% documented in other studies \[[@pone.0132889.ref009], [@pone.0132889.ref011]\]. The underlying reason for the diverse results may be the difference in the surgical procedures for the included patients in the included studies. The pooled OR 0.69 demonstrated that MIO could significantly reduce the risk of IHM, when compared with OE, which was consistent with the results from other studies \[[@pone.0132889.ref004], [@pone.0132889.ref068]\]. The main superiority of MIO over conventional OE was minimal trauma, since in MIO, the operation could be done through small incision, avoiding the trauma of open operation \[[@pone.0132889.ref009]\]. Moreover, the bias in the selection of patients should be taken into consideration, that is, patients selected for MIO were always in early stages of esophageal cancer, with smaller tumors and lower risk in the occurrence of postoperative complications than patients of late stages.

Pulmonary complications (PCs) are the most frequent morbidity event after oesophagectomy. At least half the patients are at risk for developing PCs after open oesophagectomy performed through a right thoracotomy and laparotomy \[[@pone.0132889.ref009]\]. In addition, researchers even have reported that the occurrence of PCs are correlated with in-hospital mortality and prolonged hospital stay \[[@pone.0132889.ref006],[@pone.0132889.ref103]\]. Therefore, theoretically, we hypothesize that MIO can reduce the rate of PCs and thereby reduce the risk of IHM. The most basic reasons for this hypothesis are the less invasive nature of the procedure and reduced deterioration of the ventilatory mechanism than is observed after the open procedure through avoiding thoracotomy and laparotomy \[[@pone.0132889.ref009],[@pone.0132889.ref104]\]. The hypothesis was confirmed in a recently reported multicentre, randomised controlled trial, which found the occurrence of PCs in OE group (29%) was three times more than the MIO group (9%) \[[@pone.0132889.ref003]\]. In our analysis, when compared to the OE group, the MIO group showed a reduced morbidity of PCs, with the overall PCs morbidity of 19.2% (2,613/13,585). This was consistent with the result of 3.1%-37.0% from other studies \[[@pone.0132889.ref003], [@pone.0132889.ref068], [@pone.0132889.ref103]\]. Moreover, the pooled RR of 0.73 indicated that sufficient evidence was available for validation of the superiority of MIO in reducing PCs, with a statistically significant heterogeneity. We also found that two studies reported by Nafteux \[[@pone.0132889.ref067]\] and Mamidanna \[[@pone.0132889.ref072]\] due to not taking the TNM stage into account, were the source of heterogeneity. A consistent result from the subgroup analysis after removing the two above- mentioned studies \[[@pone.0132889.ref067], [@pone.0132889.ref072]\] further confirmed the superiority of MIO in reducing the risk of PCs.

We know that cancer patients have a higher risk of deep venous thrombosis (DVT) and even pulmonary embolism (PE) when compared to the general population \[[@pone.0132889.ref105]\]. And PE has been considered to be associated with arrhythmia, especially atrial fibrillation (AF). Moreover, PE and arrhythmia are recognized as common problems that cause significant morbidity and mortality in modern societies \[[@pone.0132889.ref106]\]. Hence prevention of postoperative PE and arrhythmia is crucial in reducing the risk of IHM in patients with esophagus carcinoma. Interestingly, it was found in this study that MIO was associated with decreased incidences of PE and arrhythmia. The most fundamental reason for this association is also the less invasive nature of MIO, after which patients easily comply with doctor\'s advice and start to ambulate as soon as possible. And early ambulation contributes to prevention of thrombosis and thereby prevents the occurrence of PE \[[@pone.0132889.ref107]\]. In addition, the perforation of minimally invasive surgery per se could decrease the risk factors leading to postoperative cardiac arrhythmia \[[@pone.0132889.ref108]\]. Therefore, it is reasonable to assume that minimally invasive surgery can mitigate the risk of hospital mortality by reducing the chances of PE and arrhythmia.

Anastomotic leakages (ALs) and gastric tip necrosis (GTN) are fatal complications after oesophagectomyandcan be viewed as catastrophic events \[[@pone.0132889.ref108]\]. Therefore, the prevention of ALs and GTN appear quite important. In our analysis, no significant difference was found in the occurrence of ALs or GTN between the MIO and OE groups. Such findings indicated that there is still insufficient evidence at present to support the hypothesis that MIO can reduce the occurrence of ALs or GTN for patients with resectable esophageal cancer.

Our meta-analysis has some limitations that might affect the interpretation of the results. First, of the included studies, only one was randomized controlled trial (RCT). The remaining 47 studies used a case-control or cross-sectional design, which is susceptible to recall and selection biases. Therefore, to a certain extent, the included studies cannot provide good evidence for potential treatment effects/ harms, compared to RCTs. Second, the included studies were clinically heterogeneous in some aspects, although the statistical heterogeneity was low. For example, there exists difference in study design, demographics of participants, surgical intervention, operative details, histopathological type, even the outcome reporting after esophageal cancer surgery \[[@pone.0132889.ref103]\]. Thirdly, we have to emphasize the selection bias in TNM stage of esophageal cancer, that is, patients in MIO group had a higher proportion of early stages when compared to that OE group, although only 31 studies totaling in 4440 cases involved TNM stages. Such bias could result in a lower risk in the occurrence of postoperative complications. However, we were unable to account for these differences, despite the use of appropriate meta-analytic techniques. These limitations may result in an overestimation or underestimation of the effect of MIO. In addition, unmeasured or residual confounding is likely to be present, for instance, the intraoperative collateral tissue damage, bleeding, or worsening organ failure due to surgical trauma.

In conclusion, our research has demonstrated that MIO has superiority in decreasing the incidence of in-hospital mortality, which reinforces the idea that this strategy should be considered as a first-line surgical procedure in esophageal surgery. The decrease in in-hospital mortality by MIO was attributed to the reduction in occurrence of PCs, PE and arrhythmia for patients with resectable esophageal cancer. In addition, more proof is needed for the hypothesis that AL or GTN are two significant contributors to reducing the occurrence of in-hospital mortality.
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